Green Michael F
760 Westwood Plaza, Rm 27-462 Los Angeles, CA 90024
J Clin Psychiatry. 2016 Feb;77 Suppl 2:8-11. doi: 10.4088/JCP.14074su1c.02.
Schizophrenia is a severely disabling disease that affects millions of people worldwide. The notion of recovery from schizophrenia has recently become a topic of both research and clinical focus. With the advent of antipsychotic medications in the 1950s, many more patients achieved symptom remission than ever before. However, less than half of all patients have been able to achieve recovery. With so many drugs available to improve the symptoms of schizophrenia, why is the disorder still associated with such severe disability? In the last couple of decades, researchers and clinicians have begun to realize that a hindrance to widespread recovery is that available antipsychotic medications have been effective in treating the positive symptoms (hallucinations and delusions) of schizophrenia but not other features of illness such as cognitive impairment. Dysfunction in cognition and social cognition has a significant impact on patients' functional status, meaning that impaired cognition and social cognition should be treatment targets to improve the likelihood of recovery.
精神分裂症是一种严重致残的疾病，影响着全球数百万人。从精神分裂症中康复的概念最近已成为研究和临床关注的主题。随着20世纪50年代抗精神病药物的出现，实现症状缓解的患者比以往任何时候都多。然而，所有患者中只有不到一半能够实现康复。有这么多药物可用于改善精神分裂症的症状，为什么这种疾病仍然与如此严重的残疾相关？在过去几十年中，研究人员和临床医生开始意识到，广泛康复的一个障碍是现有的抗精神病药物在治疗精神分裂症的阳性症状（幻觉和妄想）方面有效，但对疾病的其他特征如认知障碍无效。认知和社会认知功能障碍对患者的功能状态有重大影响，这意味着认知和社会认知受损应成为改善康复可能性的治疗目标。
